Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: Diagnosis and treatment

Clinical Research in Cardiology

Volumn 96, Issue 2, 2007, Pages 61-69

  Said, Samir M ^a   Hahn, Judit ^b   Schleyer, Eberhard ^a   Müller, Marc ^b   Fiedler, Georg Martin ^b   Buerke, Michael ^c   Prondzinsky, Roland ^a  

^a Carl von Basedow Klinikum Merseburg   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Glycoprotein IIb IIIa antagonists; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CEPHALOSPORIN; CLOPIDOGREL; DANAPAROID; EPTIFIBATIDE; EZETIMIBE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; PHENYTOIN; PLACEBO; QUINIDINE; QUININE; RIFAMPICIN; SULFONAMIDE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; VANCOMYCIN;

AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG REEXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FALSE POSITIVE RESULT; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART TAMPONADE; HEMATOMA; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INJECTION SITE BLEEDING; LABORATORY DIAGNOSIS; LOADING DRUG DOSE; MONOTHERAPY; PATHOGENESIS; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOLOGICAL PARAMETERS; PLASMAPHERESIS; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE;

ACUTE DISEASE; BLOOD TRANSFUSION; CORONARY DISEASE; DIAGNOSIS, DIFFERENTIAL; DRUG MONITORING; HUMANS; PLASMAPHERESIS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RENAL DIALYSIS; RISK FACTORS; THROMBOCYTOPENIA; TIME FACTORS;

EID: 33846897804     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-0459-7     Document Type: Review

References (58)

1. Abrams CS, Cines DB (2004) Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa Inhibitors. Curr Hematol Rep 3:143-147
2. Aster RH (1995) Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332:1374-1376
3. Aster RH (1999) Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 36:2-6
4. Aster RH (2005) Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127:53-59
5. Becker PS, Miller VT (1989) Heparin-induced thrombocytopenia. Stroke 20:1449-1459
6. Bennett JS, Mousa S (2001) Platelet function inhibitors in the year 2000. Thromb Haemost 85:395-400
7. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE (1997) Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 95:809-813
8. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM (1998) Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for prevention of ischemic complication (EPIC) study group. J Am Coll Cardiol 32:311-319
9. Billheimer JT, Dicker IB, Wynn R et al (2002) Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 99:3540-3546
10. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100:2071-2076
11. Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH (2002) Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost 88:892-897
12. Chong BH, Berndt MC (1989) Heparin-induced thrombocytopenia. Blut 58:53-57
13. Chong BH, Fawaz I, Chesterman CN, Berndt MC (1989) Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 73:235-240
14. Cines DB (1998) Glycoprotein IIb/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J 135:152-159
15. Cines DB, Tomaski A, Tannenbaum S (1987) Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581-589
16. Coons JC, Barcelona RA, Freedy T, Hagerty MF (2005) Eptifibatide- associated acute, profound thrombocytopenia. Ann Pharmacother 39:368-372
17. Cummings JM, Mason TJ, Chomka EV, Pouget JM (1986) Fibrinolytic therapy of acute myocardial infarction in the heparin thrombosis syndrome. Am Heart J 112:407-409
18. Curtis BR, Divgi A, Garritty M, Aster RH (2004) Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2:985-992
19. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99:2054-2059
20. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ (2000) Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 140:206-211
21. Desai M, Lucore CL (2000) Uneventful use of Tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol 12:109-112
22. Eisenlohr H, Trenkwalder P, Lydtin H (1992) Heparininduziertes Thrombose-Thrombozytopeniesyndrom bei M. Crohn. Internist 33:432-434
23. Erni J, Frey HR, Locher G (1987) Das heparin-induzierte Thrombose-Thrombozytopeniesyndrom. Dtsch Med Wochenschr 112:801-805
24. ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary artery stent implantation. Lancet 356:2037-2044
25. Frelinger AL 3rd, Lam SC, Plow EF, Smith MA, Loftus JC, Ginsberg MH (1988) Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 263:12397-12402
26. Granada JF, Kleiman NS (2004) Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting. Am J Cardiovasc Drugs 4:31-41
27. Green D, Martin GJ, Shoichet SH, DeBacker N, Bomalaski JS, Lind RN (1984) Thrombocytopenia in a prospective, randomized double-blind trial of bovine and porcine heparin. Am J Med Sci 288:60-64
28. Greinacher A, Liebenhoff U, Kiefel V, Presek P, Mueller-Eckhardt C (1994) Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose i.v. Ig G. Thromb Haemost 71:641-645
29. Guzzo JA, Nichols TC (1999) Possible anaphylactic reaction to abciximab. Catheter Cardiovasc Interv 48:71-73
30. Hermanns B, Janssens U, Handt S, Fuzesi L (1998) Pathomorphological aspects of heparin-induced thrombocytopenia II (HIT-II syndrome). Virchows Arch 432:541-546
31. Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, Matsuzawa Y (1998) Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signalling. Blood 92:3675-3683
32. Hongo RH, Brent BN (2001) Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 88:428-431
33. Huynh T, Piazza N, DiBattiste PM, Snapinn SM, Wan Y, Pharand C, Theroux P (2005) Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights form the PRISM-PLUS study. Int J Cardiol 100:73-78
34. Iakovou Y, Manginas A, Melissari E, Cokkinos DV (2001) Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty. Cardiology 95:215-216
35. Jenkins LA, Lau S, Crawford M, Keung YK (1998) Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 97:1214-1215
36. Karow T, Lang-Roth R (2004) Pharmakotherapie arterieller und venöser Durchblutungsstörungen. Allgemeine und Spezielle Pharmakologie und Toxikologie 12. Auflage, pp 296-305
37. Kereiakes DJ (1999) Oral platelet glycoprotein IIb/IIIa inhibitors. Coron Artery Dis 10:581-594
38. Kondo K, Umemura K (2002) Clinical pharmacokinetics of tirofiban, a non-peptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet 41:187-195
39. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE (1998) Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery form GP IIb/IIIa receptor blockade. Circulation 97:1680-1686
40. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA (1999) Clinical significance of thrombocytopenia during non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa inhibitors in unstable angina: Receptor suppression using inegrilin therapy (PURSUIT) trial experience. Circulation 99:2892-2900
41. McGuire DK, Newby LK (2000) Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial. J Thromb Thrombolysis 10:111-119
42. Moshiri S, Di Mario C, Liistro F, Melissano G, Chiesa R, Colombo A (2001) Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis. Catheter Cardiovasc Interv 53:225-228
43. Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, Lecompte T, de Maistre E (2004) Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol 77:67-71
44. Patel S, Patel M, Din I, Reddy CV, Kassotis J (2005) Profound thrombocytopenia associated with Tirofiban-case report and review of literature. Angiology 56:351-355
45. Payne BA, Pierre RV (1984) Pseudothrombocytopenia: a laboratory artefact with potentially serious consequences. Mayo Clinic Proc 59:123-125
46. Phillips DR, Scarborough RM (1997) Clinical pharmacology of eptifibatide. Am J Cardiol 80:11-20
47. Popma JJ, Berger P, Ohman EM, Harrigton RA, Grines C, Weitz JI (2004) Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:576-599
48. PURSUIT Investigators (1998) Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrillin therapy. N Engl J Med 339:436-443
49. Rao J, Mascarenhas DA (2001) Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia. J Invasive Cardiol 13:471-473
50. Reddy MS, Carmody TJ, Kereiakes DJ (2001) Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv 52:486-488
51. Rizvi MA, Kojouri K, George JN (2001) Drug-induced thrombocytopenia: an update systematic review. Ann Intern Med 134:346
52. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, Simoons ML, Califf RM (2000) Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36:75-83
53. Seiffert D, Stern AM, Ebling W, Rossi RJ, Barrett YC, Wynn R, Hollis GF, He B, Kieras CJ, Pedicord DL, Cromley DA, Hua TA, Stein RB, Daly RN, Sferruzza A, Pieniaszek HJ, Billheimer JT (2003) Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood 101:58-63
54. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH (2003) Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 1:392-394
55. Tcheng JE (2000) Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 139:38-45
56. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA (2001) Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104:870-875
57. Vahdat B, Canavy I, Fourcade L, Garcia E, Quilici J, Bonnet JL, Bory M (2000) Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv 49:177-180
58. Yoder M, Edwards RF (2002) Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 36:628-630